BioMarin Pharma (BMRN) Posts Q4 Loss of $0.53
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $54.38 -1.82%
EPS Growth %: +1,008.3%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
SODI, PGR, OMID, More
EPS Growth %: +1,008.3%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
SODI, PGR, OMID, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.53), which may not compare to the analyst estimate of ($0.38). Revenue for the quarter came in at $300 million versus the consensus estimate of $295.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- AZZ jumps over 3% on record Q2 sales, raised guidance
- JPMorgan shares edge lower after third-quarter FICC revenue miss
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
